NDA 212018 · Janssen Biotech
Balversa
Erdafitinib · Oral · Kinase Inhibitor
NovelBreakthrough therapyAccelerated approvalPriority reviewLast checked: Nov 20, 2026Latest source record: Oct 17, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Apr 12, 2019
Approved uses
3
Original approval plus efficacy supplements
Registered trials
39
3 Phase 3, 4 recruiting
FAERS reports
1,247
919 serious, 349 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 24, 2025.
BALVERSA is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Select patients for therapy based on an FDA-approved companion diagnostic for BALVERSA [see Dosage and Administration (2.1) and Clinical Studies (14.1) ] . BALVERSA is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Select patients for therapy based on an FDA-approved companion diagnostic for BALVERSA. ( 1 , 2.1 ) Limitations of Use BALVERSA is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. ( 1 , 14.1 ) Limitations of Use BALVERSA is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy [see Clinical Studies (14.1) ] .
Mechanism: Erdafitinib is a kinase inhibitor that binds to and inhibits enzymatic activity of FGFR1, FGFR2, FGFR3 and FGFR4 based on in vitro data. Erdafitinib inhibited FGFR phosphorylation and signaling and decreased cell viability in cell lines expressing FGFR genetic alterations, including point mutations, amplifications, and fusions. Erdafitinib demonstrated antitumor activity in FGFR-expressing cell lines and xenograft models derived from tumor types, including bladder cancer.
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 19, 2024 Supplement 8 · Efficacy · priority review LabelLetter
- Jan 19, 2024 Supplement 9 · Efficacy · priority review LabelLetter
- Apr 12, 2019 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalLabelLetterReview
3 products under this application
- BALVERSA · ERDAFITINIB 3MG · TABLET, ORAL · Prescription
- BALVERSA · ERDAFITINIB 4MG · TABLET, ORAL · Prescription
- BALVERSA · ERDAFITINIB 5MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Erdafitinib" as an intervention, any sponsor and status, largest first.
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruiting
National Cancer Institute (NCI)NIH
NCT02465060 · 6,452 participants (planned) · Start Aug 17, 2015 · Primary completion Dec 31, 2027
Drug: Adavosertib; Afatinib and 30 more · For: Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Bladder Carcinoma and 49 more
Sites: Birmingham, Alabama; Fairhope, Alabama; Mobile, Alabama · 1,410 sites in all
The Netherlands Cancer InstituteAcademic, hospital or other
NCT02925234 · 1,550 participants (planned) · Start Aug 2016 · Primary completion Sep 2027
Drug: Panitumumab; Olaparib and 35 more · For: Cancer; Tumors; Neoplasm and 1 more
Sites: Alkmaar, Netherlands; Almelo, Netherlands; Amersfoort, Netherlands · 36 sites in all
National Cancer Institute (NCI)NIH
NCT03155620 · 1,377 participants · Start Jul 31, 2017 · Primary completion Mar 31, 2025
Drug: Ensartinib; Erdafitinib and 11 more · For: Advanced Malignant Solid Neoplasm; Ann Arbor Stage III Non-Hodgkin Lymphoma; Ann Arbor Stage IV Non-Hodgkin Lymphoma and 42 more
Sites: Birmingham, Alabama; Anchorage, Alaska; Mesa, Arizona · 172 sites in all
- A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder CancerPivotal-lookingRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT06319820 · 641 participants (planned) · Start Apr 18, 2024 · Primary completion Jun 28, 2028
Drug: Gemcitabine; MMC · For: Non-Muscle Invasive Bladder Neoplasms
Sites: Little Rock, Arkansas; Los Alamitos, California; Los Angeles, California · 193 sites in all
- A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene AberrationsPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT03390504 · 629 participants · Start Mar 23, 2018 · Primary completion Apr 15, 2024
Drug: Erdafitinib; Vinflunine and 2 more · For: Urothelial Cancer
Sites: Anchorage, Alaska; Sacramento, California; St. Helena, California · 345 sites in all
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT04083976 · 316 participants · Start Nov 20, 2019 · Primary completion Dec 4, 2023
Drug: Erdafitinib · For: Advanced Solid Tumor
Sites: Tucson, Arizona; Colorado Springs, Colorado; Hollywood, Florida · 179 sites in all
- An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial CancerActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT02365597 · 239 participants · Start Apr 22, 2015 · Primary completion Sep 15, 2022
Drug: Erdafitinib; Midazolam and 1 more · For: Urothelial Cancer
Sites: Sedona, Arizona; Los Angeles, California; Orange, California · 105 sites in all
- Study of Erdafitinib Intravesical Delivery System for Localized Bladder CancerActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT05316155 · 235 participants · Start Apr 11, 2022 · Primary completion Mar 30, 2028
Drug: Erdafitinib Intravesical Delivery System · For: Non-Muscle Invasive Bladder Neoplasms
Sites: Birmingham, Alabama; Los Angeles, California; Lone Tree, Colorado · 59 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death272
- off label use104
- diarrhoea100
- stomatitis82
- onycholysis58
- fatigue53
- hyperphosphataemia53
- nail disorder53
- dry mouth46
- nail discolouration45
- dry eye43
- disease progression42
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2018 | 1 |
| 2019 | 79 |
| 2020 | 234 |
| 2021 | 193 |
| 2022 | 246 |
| 2023 | 142 |
| 2024 | 154 |
| 2025 | 106 |
| 2026 | 92 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Balversa (Erdafitinib)
2024 spending
$22.7M
Beneficiaries
305
1,123 claims
Per beneficiary
$74,345
$443.00 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $15,867,593 |
| 2021 | $14,992,685 |
| 2022 | $16,785,721 |
| 2023 | $17,690,617 |
| 2024 | $22,675,188 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.
Loriot Y, Necchi A, Park SH, et al. · N Engl J Med 2019 · Clinical Trial, Phase II, Multicenter Study
- Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer.
Catto JWF, Tran B, Rouprêt M, et al. · Ann Oncol 2024 · Randomized Controlled Trial
- Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.
Loriot Y, Matsubara N, Park SH, et al. · N Engl J Med 2023 · Clinical Trial, Phase III, Comparative Study
- Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study.
Pant S, Schuler M, Iyer G, et al. · Lancet Oncol 2023 · Clinical Trial, Phase II, Research Support, Non-U.S. Gov't
- Erdafitinib versus Chemotherapy in Fibroblast Growth Factor Receptor-Altered Advanced or Metastatic Urothelial Cancer After Progression on Anti-programmed Death-(Ligand) 1 Therapy: An Exploratory Analysis of the Asian Subpopulation in the THOR Phase 3 Study.
Matsubara N, Loriot Y, Burgess EF, et al. · Clin Genitourin Cancer 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Erdafitinib or Erdafitinib Plus Cetrelimab for Patients With Metastatic Urothelial Carcinoma and FGFR Alterations: Final Results From the Phase II NORSE Study.
Loriot Y, Powles T, Moreno V, et al. · J Clin Oncol 2026 · Clinical Trial, Phase II, Randomized Controlled Trial
Sponsor: Johnson & Johnson (Janssen)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.